Professor Nicholas Barnes is Professor of Neuropharmacology within the Institute of Clinical Sciences, and has been at the University of Birmingham Medical School since 1991. He is a World renowned translational pharmacologist with a h-index of 46 and current grant income as PI over £2m. His research group investigate from cellular and molecular mechanisms to clinical trials. Professor Barnes is also the Principal Founder of Celentyx Ltd, a venture capital funded pharmaceutical research and development company focusing on diseases of the immune system and immuno-oncology.
Current live funding as PI = £2,137,690
Including grants from the Medical Research Council (3), MoD (UK) and pharmaceutical industry
Number of research papers = 131 (including the most highly cited paper ever from the University of Birmingham)
Current h-index = 46
Current research group = 4 post-docs, 5 PhD students, 1 research tech